A double‐blind, randomized, placebo‐controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca

Abstract

Treatment with cevimeline at a dosage of 30 mg 3 times daily resulted in substantive improvement by increasing the rate of saliva and tear flow in patients with Sjögren's syndrome, as well as improving subjective symptoms of dry mouth, dry eyes, and overall dryness. The 15-mg dosage relieved some symptoms, and both dosages were well tolerated.